硕士生导师简历

基本信息

姓名： 贾殿隆

职称： 副教授

学历： 博士

电话：13969514677

电子信箱：jiadianlong@lcu.edu.cn

出生年月：1989.05

研究方向： 生物技术药物，药物靶向递送

毕业学校： 四川大学

1. 研究工作简介

主要从事肿瘤靶向和免疫治疗蛋白分子的设计与纳米药物递送的研究。近年来主持山东省自然科学基金一项，山东省自然科学基金重点项目子课题一项。

1. 发表论文

[1] Jia, D., Lu, Y., Lv, M., Wang, F., Lu, X., Zhu, W., Wei, J., Guo, W., Liu, R., Li, G., Wang, R., Li, J., & Yuan, F. (2023). Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy. Journal of controlled release, 360, 858–871.

[2] Jia, D., Zhao, S., Liu, H., Zhan, X., Zhou, Z., Lv, M., Tang, X., Guo, W., Li, H., Sun, L., Zhong, Y., Tian, B., Yuan, D., Tang, X., & Fan, Q. (2024). ICG-labeled PD-L1-antagonistic affibody dimer for tumor imaging and enhancement of tumor photothermal-immunotherapy. International journal of biological macromolecules, 269(Pt 2), 132058.

[3] Lu, X., Zhan, X., Xia, G., Wang, F., Lv, M., Liu, R., Liu, Y., Zi, C., Li, G., Wang, R., Li, J., Yuan, F., & Jia, D. (2025). Improving Targeted Delivery and Antitumor Efficacy of TRAIL through Fusion with a B7H3-Antagonistic Affibody. Molecular pharmaceutics, 22(1), 284–294.

[4] D. Jia, H. Liu, S. Zheng, D. Yuan, R. Sun, F. Wang, Y. Li, H. Li, F. Yuan, Q. Fan, Z. Zhao, ICG-Dimeric Her2-Specific Affibody Conjugates for Tumor Imaging and Photothermal Therapy for Her2-Positive Tumors, Mol Pharm, 20 (2023) 427-437.

[5] R. Chang, R. Fu, Y. Huang, J. Zhang, C. Feng, R. Wang, H. Yan, G. Li, X. Chu, F. Yuan, D. Jia, J. Li, Codelivery of TRAIL and Mitomycin C via Liposomes Shows Improved Antitumor Effect on TRAIL-Resistant Tumors, Mol Pharm, 20 (2023) 2864-2875.

[6] H. Liu, D. Jia, F. Yuan, F. Wang, D. Wei, X. Tang, B. Tian, S. Zheng, R. Sun, J. Shi, Q. Fan, Her3-specific affibody mediated tumor targeting delivery of ICG enhanced the photothermal therapy against Her3-positive tumors, Int J Pharm, 617 (2022) 121609.

[7] D. Jia, F. Wang, Y. Yang, P. Hu, H. Song, Y. Lu, R. Wang, G. Li, R. Liu, J. Li, F. Yuan, Coupling EGFR-Antagonistic Affibody Enhanced Therapeutic Effects of Cisplatin Liposomes in EGFR-expressing Tumor Models, J Pharm Sci, 111 (2022) 450-457.

[8] D. Jia, F. Wang, Y. Lu, P. Hu, R. Wang, G. Li, R. Liu, J. Li, H. Liu, Q. Fan, F. Yuan, Fusion of an EGFR-antagonistic affibody enhances the anti-tumor effect of TRAIL to EGFR positive tumors, Int J Pharm, 620 (2022) 121746.

[9] H. Wang, D. Jia, D. Yuan, X. Yin, F. Yuan, F. Wang, W. Shi, H. Li, L.M. Zhu, Q. Fan, Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy, J Nanobiotechnology, 19 (2021) 138.

[10] D. Jia, Y. Yang, F. Yuan, Q. Fan, F. Wang, Y. Huang, H. Song, P. Hu, R. Wang, G. Li, R. Liu, J. Li, Increasing the antitumor efficacy of doxorubicin liposomes with coupling an anti-EGFR affibody in EGFR-expressing tumor models, Int J Pharm, 586 (2020) 119541.

[11] Q. Nie, D. Jia, H. Yang, Y. Feng, Q. Fan, Q. Shi, L. Wan, X. Lu, Conjugation to 10 kDa Linear PEG Extends Serum Half-Life and Preserves the Receptor-Binding Ability of mmTRAIL with Minimal Stimulation of PEG-Specific Antibodies, Mol Pharm, 14 (2017) 502-512.